Internal link ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results February 27, 2019 at 12:00 PM UTC
Internal link ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day January 29, 2019 at 01:30 PM UTC
Internal link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10 January 07, 2019 at 12:00 PM UTC
Internal link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2 January 02, 2019 at 12:00 PM UTC